NovoCure Limited (NASDAQ:NVCR) was a big mover last session, as the company saw its shares rise over 10% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $14.75 to $18.15 in the past one-month time frame.
The move came after the company announced that it will be presenting new data for its novel cancer treatment at a medical conference this week.
The company has not seen any estimate revisions over the past few weeks, and its Zacks Consensus Estimate for the current quarter hasn’t been in a trend either. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
NovoCure currently has a Zacks Rank #2 (Buy) while its Earnings ESP is 0.00%.
NovoCure Limited Price and Consensus
A better-ranked stock in the Medical Services industry is Healthways, Inc. (NASDAQ:TVTY) , which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is NVCR going up? Or down? Predict to see what others think: Up or Down
More Stock News: 8 Companies Verge on Apple-Like Run
Did you miss Apple (NASDAQ:AAPL)'s 9X stock explosion after they launched their iPhone in 2007? Now 2017 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs.
A bonus Zacks Special Report names this breakthrough and the 8 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains. Click to see them right now >>
NovoCure Limited (NVCR): Free Stock Analysis Report
Healthways, Inc. (TVTY): Free Stock Analysis Report
Original post
Zacks Investment Research